Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 11, 2014

View Archived Issues

Protein-modified red blood cells engineered to deliver systemic payloads

Takeda Pharmaceutical reviews highlights of first quarter of fiscal 2014

Genetic modification of T-cell epitopes in therapeutic toxins to minimize immunogenic reactions

Valneva signs cell-line license agreement with GeoVax

Alvogen adds to Asian assets with acquisition of Dream Pharma

Mesoblast to collaborate with NIH on trial for stem cell therapy in heart failure

Cara Therapeutics initiates phase II trial of CR-845 in uremic pruritus

New Amsterdam Sciences studying NAS-911 as a co-therapeutic for influenza

Yabao Pharmaceuticals and Changzhou Le Sun Pharmaceuticals to develop oncology drug

New antisense oligonucleotides patented by Japanese group

Palobiofarma designs novel PDE10A inhibitors

Novo Nordisk offers overview of second quarter 2014

Leica Biosystems and Bristol-Myers Squibb collaborate on companion diagnostics

Novel agents for HCV infection disclosed by Bristol-Myers Squibb

Clinuvel declines Retrophin proposal

Novartis divulges novel Mdm2 and Mdm4 interaction inhibitors

OPKO Health submits IND for Rayaldee as an adjunctive cancer therapy

Trillium Therapeutics expands CD47 program into solid tumors

Chinese and U.S. researchers disclose novel antibacterial marinopyrrole derivatives

Oxygen Biotherapeutics confirms collaboration with Imperial College London

Baxter opens biologics facility with plans for expansion

FDA approves Invokamet for type 2 diabetes

Reversible non-peptide proteasome inhibitors as potential anticancer agents

Eylea approved in E.U. for DME

Daiichi Sankyo and Charleston Laboratories develop fixed-dose combination hydrocodone products

FDA approves Velcade for retreatment of multiple myeloma

Genentech files for U.S. approval of Lucentis for diabetic retinopathy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...